Summary  
ECOG-ACRIN Cancer Research Group’s Marketing/Clinical Education and Awareness staff will use approved language/images to help increase awareness of EA8184 and support accrual efforts. The content below may be shared to the ECOG-ACRIN website, affiliated blogs, and social media channels. Links to these channels are included below. Staff at participating ECOG-ACRIN sites may also use this content on their own institutions’ marketing/communications channels.

ECOG-ACRIN Website  
<https://www.ecog-acrin.org>

ECOG-ACRIN Blogs  
<https://blog-ecog-acrin.org>  
<https://advocacy-ecog-acrin.org>

Social Media Channels  
Twitter: <https://twitter.com/eaonc>  
Facebook: <https://www.facebook.com/eaonc/>   
LinkedIn: <https://www.linkedin.com/company/ecog-acrin-cancer-research-group/>  
YouTube (*video only*): <https://www.youtube.com/channel/UCAC_V1QdqlH2KdHOt7K2IHw>

Target Audience(s)  
The prostate cancer community, including:

* Patients and survivors
* Caregivers
* Advocates
* Research, education, and advocacy organizations

Privacy/Confidentiality Considerations  
ECOG-ACRIN will make every possible effort to protect privacy and confidentiality by:

* Keeping social media post content general in nature and avoiding any specifics related to the trial or patients on the trial
* Refraining from direct engagement with individuals about their eligibility for trials
  + Instead, individuals will be directed to consult with their physician and/or the NCI’s Cancer Information Service
* Monitoring posts daily for inappropriate responses/interactions and flagging or removing as needed

General/Website Messaging

**EA8184 Study**


*To Evaluate if Green Tea can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring*

**Why consider participating in this study?**

* Research studies are conducted to try to answer questions about how to prevent, diagnose, and treat diseases like cancer.
* Studies have shown that “active surveillance” is a recommended option for men who have been diagnosed with low risk prostate cancer. This involves close monitoring with a prostate-specific antigen (PSA) test, a digital rectal exam (DRE), prostate biopsies, and imaging tests.
* EA8184 will compare active surveillance alone to active surveillance with the study drug, Sunphenon® 90D (containing green tea catechins).
* The purpose of the EA8184 study is to find out if Sunphenon® 90D can help prevent the progression of prostate cancer (from a low risk stage to a higher risk stage) in men who are on active surveillance.

**What does this study involve?**

* If you decide to take part in EA8184, you will be assigned by chance (randomized) to one of the two groups listed below. Neither you nor your doctor will be told which group you are in, but your doctor can find out if it is necessary to know for your health.
  + **Group 1**: You will get the study drug Sunphenon® 90D. This will be three pills, taken by mouth two times a day for 6 months.
  + **Group 2**: You will get the placebo pills for 6 months. A placebo pill looks like the study drug, but contains no medication. This will be three pills, taken by mouth two times a day for 6 months.



* At the end of the 6 months, after you finish your study treatment with the study drug or placebo, your doctor will contact you by phone to ask how you are doing. You will also need to visit the clinic for a standard of care biopsy.
* Your doctor will follow your condition for an additional 6 months.
* You can decide to stop taking part in the study at any time, even after you have enrolled.

**Who will take part in this study?**

* Approximately 360 people will take part in EA8184.
* Participants must be at least 21 years old, speak English or Spanish, and have biopsy-proven adenocarcinoma of the prostate.
* Only participants who are on active surveillance will be included in this study (i.e., not participants that are using radiation or surgery to treat their prostate cancer).
  + Participants must not have had previous treatment for their prostate cancer.

**What are the costs of taking part in this study?**

* Just as you would if you were getting the usual care for your cancer, you and/or your insurance plan will need to pay for some or all of the costs of medical care you get as part of this study. Check with your insurance company to find out what they will pay for.
* You/your insurance provider will **not** have to pay for Sunphenon® 90D, or the following exams, tests, and procedures while you take part in this study:
  + Hepatitis B & C tests (prior to the start of the study)
  + Gleason Score confirmation and % Ki-67 expression assessment (at the start and end of the study)
  + Apoptosis by caspase and tissue Nf-kB (start and end of the study)
  + Plasma catechins (start and end of the study)
* You/your insurance provider will **not** have to pay to send your tissue from the biopsy.
* For more information on insurance coverage and clinical trials, visit the National Cancer Institute (NCI) website at: www.cancer.gov/clinicaltrials/learningabout/payingfor or call 1-800-4-CANCER (1-800-422-6237).

**How can you learn more or sign up for the trial?**

About the EA8184 study, talk with your doctor or:

* Visit www.ecog-acrin.org and search EA8184, then select the link to EA8184.
  + If you are seeking information about the locations where the study is available, scroll down the page to Locations and Contacts.
* Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237)

About clinical trials:

* General cancer information: visit the NCI website at www.cancer.gov
* Insurance coverage: visit www.cancer.gov/clinicaltrials/learningabout/payingfor

About ECOG-ACRIN:

* Visit [www.ecog-acrin.org](http://www.ecog-acrin.org)
* For a list of patient resources and links to patient advocacy groups, visit <https://ecog.org/patients/resources>

Social Media Messaging

|  |  |
| --- | --- |
| **Facebook/LinkedIn** | **Twitter** |
| Clinical trial EA8184, led by Dr. Nagi Kumar of @MoffittCancerCenter, will evaluate if green tea catechins can help prevent the progression of prostate cancer in men on active surveillance. Learn more here: https://bit.ly/ea8184-trial | #Clinicaltrial EA8184, led by Dr. Nagi Kumar of @MoffittNews will evaluate if #greentea catechins can help prevent the progression of #prostatecancer in men on active surveillance. Learn more here: <https://bit.ly/ea8184-trial> #pcsm cc: @jpowsang |
| Could green tea catechins help prevent the progression of prostate cancer in men on active surveillance? Clinical trial EA8184, led by Dr. Nagi Kumar of @MoffittCancerCenter, aims to find out. Learn more: <http://bit.ly/ea8184-trial> | Could #greentea catechins help prevent the progression of #prostatecancer in men on active surveillance? #Clinicaltrial EA8184, led by Dr. Nagi Kumar of @MoffittNews, aims to find out. Learn more: <http://bit.ly/ea8184-trial> #pcsm cc: @jpowsang |
| Clinical trial EA8184 is evaluating if green tea can be effective in reducing the progression of prostate cancer in men on close monitoring. For more information: <https://bit.ly/ea8184-trial> | #Clinicaltrial EA8184 is evaluating if #greentea can be effective in reducing the progression of #prostatecancer in men on close monitoring. For more information: <https://bit.ly/ea8184-trial> #pcsm cc: @jpowsang |

**Hashtags:** #prostatecancer #pcsm #greentea

Images

